Skip to main content

Epigenomics Licenses Health Discovery's SVM Technology for DNA Methylation Analysis

NEW YORK (GenomeWeb News) - Health Discovery Corporation said today that Epigenomics has taken a non-exclusive worldwide license to its support vector machine technology for use in DNA methylation analysis.
HDC’s SVM technology is a machine-learning approach for classifying high-dimensional data. Epigenomics will use the technology in its biomarker service and collaboration business to help measure the differences in DNA methylation patterns between healthy and diseased tissues.
Financial terms of the deal were not disclosed.
The agreement is HDC’s second SVM licensing deal in the past two months. The company signed a similar agreement with Bruker Daltonics for applications in clinical proteomics in early August.
Stephen Barnhill, HDC's chairman and chief executive officer, said in a statement that the two application areas of methylation and mass spectrometry analysis “underscore the scope and power of HDC's SVM technology as the leading pattern recognition tool.”
HDC holds a large patent portfolio protecting the use of support vector machines in bioinformatics applications. In June, the firm sued Ciphergen and Equbits for infringing its SVM patent estate. Both cases are pending in the US District Court in Marshall, Texas.

Filed under

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.